Dublin, Aug. 22, 2017 -- The "Worldwide Adult Vaccines Market: Company Adult Vaccines Sales, Country Adult Vaccines, and Analysis" report has been added to Research and Markets' offering.
Adult Vaccines Market is expected to be close to US$ 20 Billion by the year 2022
Because of vaccines, some diseases (like Polio and Diphtheria) are becoming rare. Vaccination can prevent certain deadly diseases in all age groups. Almost all countries around the world have introduced efficient National Immunization Programme in their vaccination schedule to overcome the epidemics caused by vaccine-preventable diseases. WHO's Global Vaccine Action Plan, Global Immunization Vision and Strategy (GIVS), The GAVI Alliance all are putting their best to minimize the incidence of vaccine-preventable diseases which indeed is driving the adult vaccine market vigorously.
"Influenza Vaccine Leads the Adult Vaccine Market for the Year 2017"
Influenza vaccine is dominating the adult vaccine segment in year 2017, however it will lose its place to Pneumococcal vaccine in the coming future as admissions for pneumonia had almost tripled over the last 15 years. Other than Influenza and Pneumococcal Vaccines, Cervical Cancer (HPV), Hepatitis and Travel vaccines also have considerable market share in adult vaccines market.
"Considerable Growth in Immunization of Cervical Cancer (HPV), Zoster, Meningococcal, Hepatitis, Tdap and MMRV Vaccines"
In terms of Immunization; Influenza holds the maximum share as influenza vaccination is recommended to take annually in almost all countries of the world. However, with the growing awareness and efficiency of vaccines in preventing diseases, our analysis found that there will be considerably growth in the number for people opting for Cervical Cancer (HPV), Zoster, Meningococcal, Hepatitis, Tdap and MMRV vaccines in future till 2022.
"Administration of Vaccines Doses"
Influenza Vaccine holds the topmost place while talking about the administration of vaccine doses as influenza strains change every year and people needs to get an updated influenza shot each year to stay protected. Expect Influenza; Cervical Cancer (HPV), Pneumococcal and Hepatitis vaccines have remarkable administration doses.
'Worldwide Adult Vaccines Market: Company Adult Vaccines Sales, Country Adult Vaccines, and Analysis' is the 2nd publication on Adult Vaccines Market. This 181 pages research report with 77 Figures and 32 Tables provides a complete analysis of Adult Vaccines Market, Immunization Numbers in People, Number of Vaccine Doses Administered in Adults (Disease wise) & Key Players Analysis.
Key Questions Answered In This Report:
- What will be the Market Size of Global Adult Vaccine by the year 2022?
- What are the Key Drivers & Challenges for Adult Vaccines Market?
- Who are the key players in Adult Vaccine Market?
- What products are in key Players Pipeline?
Adult Vaccines in the Report have been studied from 3 Viewpoints:
1. Global Adult Vaccines (Disease wise) Market & Forecast (2011 - 2022)
2. People Immunized (Disease wise) & Forecast (2011 - 2022)
3. Doses of Vaccines Administered (Disease wise) & Forecast (2011 - 2022)
9 Vaccines Studied in the Report are as Follows:
1. Influenza
2. Cervical Cancer
3. Zoster (Shingles)
4. MMRV (Measles, Mumps, Rubella and Varicella)
5. Pneumonia
6. Meningitis
7. Hepatitis
8. DTap (Diphtheria, Tetanus, Pertussis)
9. Travel & Miscellaneous Vaccine
Companies Vaccines Sales and Forecast:
1. GlaxoSmithKline, plc Sales & Forecast (2011 - 2022)
2. Merck & Co. Sales & Forecast (2011 - 2022)
3. Sanofi Pasteur's Sales & Forecast (2011 - 2022)
4. Pfizer, Inc.'s Sales & Forecast (2011 - 2022)
5. Others Vaccines
For more information about this report visit https://www.researchandmarkets.com/research/jqmh8q/worldwide_adult
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Vaccines


Nvidia Confirms Major OpenAI Investment Amid AI Funding Race
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight
Hyundai Motor Lets Russia Plant Buyback Option Expire Amid Ongoing Ukraine War
Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand
Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees
SoftBank and Intel Partner to Develop Next-Generation Memory Chips for AI Data Centers
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex
Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 



